张德耀;陈敏山;

• 1:中山大学肿瘤防治中心肝脏外科华南肿瘤学国家重点实验室肿瘤协同创新中心

摘要(Abstract)：

原发性肝癌是全球范围内最常见的恶性肿瘤之一,其发病率居所有恶性肿瘤的第6位,死亡率居第4位。原发性肝癌中90%以上的病例为肝细胞癌(以下简称肝癌)。近几年,随着各项临床研究的开展,肝癌的治疗模式由单一的局部治疗转变为多学科综合治疗模式。2021年5月,欧洲肿瘤内科学会在Annals of Oncology杂志发布了《2021年欧洲肿瘤内科学会肝细胞癌临床实践指南更新》。本文将对指南的更新内容进行解读。

关键词(KeyWords)： 原发性肝癌;肝细胞癌;免疫治疗;进展

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81874070)

作者(Authors): 张德耀;陈敏山;

参考文献(References)：

• [1]SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.
• [2]VOGEL A,MARTINELLI E,ESMO Guidelines Committee.Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines[J].Ann Oncol,2021,32(6):801-805.
• [3]DI MARCO V,DE VITA F,KOSKINAS J,et al.Sorafenib:from literature to clinical practice[J].Ann Oncol,2013,24 Suppl 2:ii30-ii37.
• [4]KUDO M,FINN R S,QIN S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet,2018,391(10126):1163-1173.
• [5]ABOU-ALFA G K,MEYER T,CHENG A L,et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J].N Engl J Med,2018,379(1):54-63.
• [6]ZHU A X,KANG Y K,YEN C J,et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2019,20(2):282-296.
• [7]EL-KHOUEIRY A B,SANGRO B,YAU T,et al.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J].Lancet,2017,389(10088):2492-2502.
• [8]ZHU A X,FINN R S,EDELINE J,et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224):a non-randomised,open-label phase 2 trial[J].Lancet Oncol,2018,19(7):940-952.
• [9]YAU T,PARK J W,FINN R S,et al.CheckMate 459:A randomized,multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J].Ann Oncol,2019,30 Suppl 5:874-875.
• [10]FINN R S,RYOO B Y,MERLE P,et al.Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240:A Randomized,Double-Blind,Phase Ⅲ Trial[J].J Clin Oncol,2020,38(3):193-202.
• [11]LEE M S,RYOO B Y,HSU C H,et al.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140):an open-label,multicentre,phase 1b study[J].Lancet Oncol,2020,21(6):808-820.
• [12]SANGRO B,CARPANESE L,CIANNI R,et al.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages:a European evaluation[J].Hepatology,2011,54(3):868-878.
• [13]CHOW P K H,GANDHI M,TAN S B,et al.SIRveNIB:Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma[J].J Clin Oncol,2018,36(19):1913-1921.
• [14]HE M,LI Q,ZOU R,et al.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin,Fluorouracil,and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion:A Randomized Clinical Trial[J].JAMA Oncol,2019,5(7):953-960.
• [15]陈敏山，元云飞，郭荣平，等.肝动脉灌注化疗在肝癌转化治疗中的应用——中山大学肿瘤防治中心的经验总结[J].中国医学前沿杂志(电子版)，2021，13(3)：70-76.